Table 4.

Studies using ATO for remission induction

Reference	No. of patients	ATO dose	CR (%)	mCR (%)	OS
Ravandi et al. [208]	82	0.15 mg/kg + ATRA ± GO ± Ida	91	73a	85% (3y)
Hu et al. [205]	85	0.16 mg/kg + ATRA	94	100a	92% (5y)
Mathews et al. [198]	72	10 mg	86	76b	74% (5y)
Ghavamzadeh et al. [197]	197	0.15 mg/kg	86	92c	64% (5y)

Post-induction therapy: 4 courses of ATO + ATRA ± GO [208]; 3 cycles of chemotherapy followed by maintenance therapy [205]; 7 courses of ATO [198]; 4 courses of ATO [197]

ATO arsenic trioxide, ATRA all-trans retinoic acid, CR complete remission, GO gemtuzumab ozogamicin, mCR molecular complete remission, OS overall survival, y years

^aAfter consolidation

^bAfter induction

^cDuring follow-up